Phase II study of the oral MEK inhibitor selumetinib (AZD6244) in advanced acute myeloid leukemia (AML).
暂无分享，去创建一个
Scott E. Smith | R. Larson | W. Stock | L. Doyle | K. Shannon | H. Erba | M. Kirschbaum | E. Curran | P. Dy | N. Jain | O. Odenike | N. Iyengar | L. Popplewell | E. Atallah | X. Poiré | Margaret Green | R. Kunnavakkam | E. Diaz-Flores | G. Koval